Fig. 2: MECOM-amplified SKOV3 and OVSAHO ovarian cancer cells are vulnerable to epigenetic inhibitor E-JIB-04. | Cell Death Discovery

Fig. 2: MECOM-amplified SKOV3 and OVSAHO ovarian cancer cells are vulnerable to epigenetic inhibitor E-JIB-04.

From: Epigenetic targeting of MECOM/KRAS axis by JIB-04 impairs tumorigenesis and cisplatin resistance in MECOM-amplified ovarian cancer

Fig. 2

A SKOV3 cells were treated with increasing concentrations (upto 30 µM) of epigenetic inhibitors targeting histone demethylases and methyltransferase enzymes, and the percentage cell viability was measured by crystal violet staining after 72 h. Quantitative analysis of percentage cell viability of A2780, SKOV3, and OVSAHO cells upon treatment with increasing doses of E-JIB-04 (B) and Z-JIB-04 (C). IC50 values demonstrate significant growth inhibitory effects on SKOV3 and OVSAHO by both E-JIB04 and Z-JIB04 isomers, showing better growth inhibitory effects than cisplatin (D–G). Treatment with both E and Z isomers of JIB-04 at IC50 values in SKOV3 and OVSAHO cells in a time-dependent manner suggested a proliferation defect.

Back to article page